Characteristics of included studies
| Studies | Country | No | Screening instrument | Participant age (years, range) | Comparison | Duration (weeks) | Follow-up (weeks) |
|---|---|---|---|---|---|---|---|
| Addington 201125 | Canada | 51 | Structured interview for prodromal symptoms | 20.9 (NR) | CBT v supportive counselling | 26 | 52 and 78 |
| Amminger 201014, 26 | Austria | 81 | PANSS | 16.4 (NR) | Omega 3 fatty acids (1200 mg/day) v placebo | 12 | 52 |
| Bechdolf 201237, 39 | Germany | 128 | ERIraos | 25.8 (NR) | Integrated therapies v supportive counselling | 52 | 104 |
| McGlashan 200327, 54-56 | US | 60 | Structured interview for prodromal symptoms | 17.8 (12-36) | Olanzapine (8 mg/day) v placebo | 52 | 104 |
| McGorry 200230, 57 | Australia | 59 | BPRS | 20 (14-28) | Risperidone (1.3 mg/day) and CBT v supportive counselling | 26 | 156-208 |
| Morrison 200423, 58, 59 | Great Britain | 60 | PANSS | 22 (16-36) | CBT and supportive counselling v supportive counselling | 52 | 156 |
| Morrison 201128, 52 | Great Britain | 288 | CAARMS | 20.7 (14-34) | CBT and supportive counselling v supportive counselling | 26 | 104 |
| Nordentoft 200635 | Denmark | 79 | ICD-10 | 24.9 (NR) | Integrated therapies v standard treatment | 104 | NA |
| Phillips 200924, 60 | Australia | 115 | CAARMS | 17.9 (NR) | Risperidone (2 mg/day) and CBT v CBT and placebo v supportive counselling and placebo | 52 | 104 |
| Ruhrmann 200738 | Germany | 124 | Early Recognition Inventory (ERIraos) | 25.6 (NR) | Amisulpride (118.7 mg/day) and NBI v NBI | 12 | NA |
| Van der Gaag 201229, 61 | Netherlands | 201 | CAARMS | 22.7 (NR) | CBT v supportive counselling | 26 | 52 and 78 |
NR=not reported; NBI=needs based intervention.